Suppr超能文献

利用家蚕感染模型靶向革兰氏阴性菌的噬菌体的治疗潜力。

The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model.

机构信息

Antibiotic Resistance and Phage Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, 632014, India.

School of Medicine, Medical Sciences and Nutrition, Medical Microbiology, University of Aberdeen, Aberdeen, AB25 2ZD, UK.

出版信息

BMC Microbiol. 2018 Aug 31;18(1):97. doi: 10.1186/s12866-018-1234-4.

Abstract

BACKGROUND

Phage therapy is the therapeutic use of bacteriophages to treat highly drug resistant bacterial infections. The current surge in bacteriophage therapy is motivated mainly because of the emergence of antibiotic-resistant bacteria in clinics. This study evaluated the therapeutic potential of three bacteriophages isolated against Escherichia coli ec311, Klebsiella pneumoniae kp235 and Enterobacter cloacae el140 strains using Galleria mellonella. The in vitro activity of three different phages belonging to Podoviridae and Myoviridae families was studied by the double agar overlay method against multi-drug resistant strains. Larval survivability studies were performed to evaluate the potential of phages against infection using G. mellonella.

RESULTS

All the three phages were found to have potential to infect the host bacterial strains. For in vivo studies it was observed that E. coli and E. cloacae infected larvae, should be treated with three phage doses (20 μL, 10 PFU/mL) at 6 h interval to achieve 100% survival rate. But in the case of K. pneumoniae, a single phage dose treatment showed promising outcome. When mixed bacterial infections (all three bacterial cultures at 10 CFU/mL) were tested, minimum of four doses of phage cocktail (three phages) at 6 h interval was necessary to recover the larvae. All the results were confirmed by enumerating bacteria from the larvae.

CONCLUSION

Our data shows that although in vitro studies showed high infectivity of phages, for in vivo models multiple phage doses were required for effective treatment.

摘要

背景

噬菌体疗法是利用噬菌体治疗高度耐药的细菌感染的治疗方法。目前噬菌体疗法的激增主要是由于临床中出现了抗生素耐药菌。本研究评估了三种针对大肠杆菌 ec311、肺炎克雷伯菌 kp235 和阴沟肠杆菌 el140 菌株分离的噬菌体在金蝇幼虫体内的治疗潜力。通过双层琼脂覆盖法研究了属于 Podoviridae 和 Myoviridae 家族的三种不同噬菌体对多药耐药菌株的体外活性。进行幼虫存活率研究,以评估噬菌体对感染的潜在作用。

结果

所有三种噬菌体均被发现具有感染宿主细菌株的潜力。在体内研究中观察到,感染大肠杆菌和阴沟肠杆菌的幼虫应每隔 6 小时用三种噬菌体剂量(20μL、10PFU/mL)治疗,以实现 100%的存活率。但是对于肺炎克雷伯菌,单次噬菌体剂量治疗显示出有希望的结果。当测试混合细菌感染(所有三种细菌培养物均为 10CFU/mL)时,需要每隔 6 小时使用噬菌体鸡尾酒(三种噬菌体)至少四个剂量才能恢复幼虫。所有结果均通过从幼虫中计数细菌来确认。

结论

我们的数据表明,尽管体外研究显示噬菌体具有高感染力,但对于体内模型,需要多次噬菌体剂量才能进行有效治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2093/6119258/1c6f6beb6d82/12866_2018_1234_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验